MRNA is trading at $41.83 (+6.28%) after raising its 2025 revenue forecast to ~$1.9B and outlining major operating expense cuts.
- The company reiterated its goal to achieve cash breakeven by 2028.
- This upbeat guidance, delivered at the J.P. Morgan Healthcare Conference, drove a recent 15% relief rally amid a focus on cost-cutting.
- The news sparked a multi-day rally, including a 17% jump on January 13.